GG Group Ventures’s Verve Therapeutics VERV Stock Holding History

GG Group Ventures’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14,599	Closed	-$66.3K	–	56
2024 Q2	$66.3K	Buy	+14,599	New	+$91.8K	0.09%	49

Other funds holding VERV

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

GG Group Ventures's VERV Position: Q3 2024 in Review

GG Group Ventures sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 14,599 shares — an estimated $66.3K sold.

GG Group Ventures first reported a position in VERV in Q2 2024 and held it in 1 quarter. The position peaked at $66.3K in Q2 2024. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

GG Group Ventures reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
GG Group Ventures sold 14,599 Verve Therapeutics shares in Q3 2024, an estimated $66.3K.
GG Group Ventures first reported a position in Verve Therapeutics in Q2 2024 and held it in 1 quarter.
GG Group Ventures's Verve Therapeutics position peaked at $66.3K in Q2 2024.
174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on GG Group Ventures's 13F filing for Q3 2024, filed 18 Nov 2024.